Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway.
In conclusion, the results of the present study confirmed the inhibition of ALT on osteosarcoma cells via downregulation of PI3K/AKT signaling pathways, suggesting ALT as a potential therapeutic candidate for osteosarcoma.
PMID: 31974628 [PubMed - in process]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Cancer in Adolescents | Molecular Biology | Osteosarcoma | Study